Edito
Gustave Roussy & Friends Invite
- 2026 Edition
Building on the success of our first two editions, Gustave Roussy & Friends Invite 2026 continues to grow as an international space for exchange and collaboration dedicated to advancing cancer care and research. In 2025, the event brought together 165 participants, demonstrating the growing commitment of a community eager to share perspectives and collectively shape the future of oncology.
For our third edition in 2026, we are planning to step up and invite three guest centres to not only share their institutional vision, but also to debate key innovations that have recently transformed oncology, and to challenge viewpoints across different regions and continents.
We are honored to welcome:
The Netherlands Cancer Institute (Amsterdam, NETHERLANDS)
The Royal Marsden (London, ENGLAND)
Ruijin Hospital (Shangai, CHINA)
Together with Gustave Roussy, the presence of these three international centres means that four leading institutions from four countries will come together to enrich the dialogue, confront perspectives, and strengthen the global dimension of the event.
More than a scientific meeting, Gustave Roussy & Friends Invite 2026 is designed as an interactive and collaborative day where institutions, clinicians, researchers, and their broader ecosystems can engage in meaningful dialogue.
This year, the program evolves to place a much stronger emphasis on major scientific innovations, open debate, and active dialogue with the audience. The 2026 edition will feature enhanced interactive formats, dynamic exchanges between institutions, and sessions designed to spark discussion around the breakthroughs and shifts that are currently transforming oncology. Our goal is to create an even more engaging experience, where participants can confront perspectives, question established approaches, and collaboratively explore the forces shaping cancer care today and tomorrow.
Through open discussions and shared expertise, this edition reaffirms our collective ambition: to advance cancer care through collaboration, innovation, and a shared commitment to patients.
We look forward to welcoming you to this expanded and enriched edition.
